Neuvasq Showcases Promising Data at ARVO 2026

Neuvasq Biotechnologies presented promising preclinical data at ARVO 2026, showcasing multispecific Gpr124-targeting antibodies aimed at restoring the blood-retina barrier (BRB). The data focuses on NVQ401 and NVQ501, two innovative treatments showing potential in addressing retinal vascular diseases such as Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wAMD).

NVQ401, a bispecific antibody, demonstrates efficacy in activating Wnt/β-catenin signaling, reversing VEGF-induced vascular permeability, and reducing neovascularization in relevant disease models. NVQ501 expands on this by combining β-catenin activation with VEGF neutralization, showing enhanced efficacy in preclinical retinopathy models.

These findings suggest the potential of NVQ401 and NVQ501 to become new standards of care, with NVQ501 progressing towards further studies. Neuvasq emphasizes combining two clinically validated approaches to address the challenge of BRB integrity, providing much-needed therapeutic innovation.